Summary
Pfizer Inc.'s 10-Q filing for the period ending March 30, 1996, indicates a company in a period of reporting and operational activity. While the provided text is a directory listing of the filing rather than the detailed financial statements, it confirms the filing date and period. Investors interested in Pfizer during this time would look for information on sales performance, new drug development, clinical trial progress, and any significant acquisitions or divestitures. The absence of specific financial figures in this excerpt means a deeper dive into the actual 10-Q document would be necessary to assess the company's financial health and future prospects.
Key Highlights
- 1Pfizer Inc. filed its quarterly report (10-Q) for the period ending March 30, 1996, on May 13, 1996.
- 2The filing confirms Pfizer was actively reporting to the SEC as of this date.
- 3This report provides a snapshot of the company's financial and operational status during the first quarter of 1996.
- 4Investors would typically use such filings to evaluate revenue, profitability, and strategic initiatives.
- 5The presence of detailed filings implies ongoing business operations and regulatory compliance.
- 6The exact financial performance and key business developments require access to the full 10-Q document.
- 7This filing is part of the historical record for Pfizer's performance in the mid-1990s.